Trademark: MYCHELANGELO 2342140
Word
MYCHELANGELO
ID
2342140
Trademark Type
WORD
Status
Protected: Registered/protected
Application Date
29 November 2022
Registration Date
29 November 2022
Renewal Date
29 November 2032
Owner(s)
Service
Davies Collison Cave Pty Ltd
Goods and Services:
Class 5:
Pharmaceutical agents and molecules; pharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease; therapeutics containing MYC inhibiting properties.
Pharmaceutical agents and molecules; pharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease; therapeutics containing MYC inhibiting properties.
Class 42:
Scientific research in the field of DNA, mRNA, bioinformatics and genomics; pharmaceutical research services in the field of DNA, mRNA, bioinformatics and genomics; medical research in the field of DNA, mRNA,bioinformatics and genomics; technical scientific consulting services in the field of biotechnology; product development for others in the field of biotechnology; development of pharmaceutical preparations and medicines; research and development in the field of bioinformatics, biotechnology and pharmaceuticals; none of the foregoing relating to cardiovascular studies.
Scientific research in the field of DNA, mRNA, bioinformatics and genomics; pharmaceutical research services in the field of DNA, mRNA, bioinformatics and genomics; medical research in the field of DNA, mRNA,bioinformatics and genomics; technical scientific consulting services in the field of biotechnology; product development for others in the field of biotechnology; development of pharmaceutical preparations and medicines; research and development in the field of bioinformatics, biotechnology and pharmaceuticals; none of the foregoing relating to cardiovascular studies.